OBD and major US Pharma sign agreement to develop epigenetic knowledge and biomarkers to be used in the development of co-therapies for the treatment of acute myeloid leukemia (AML).
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with this.OkRead more
